Skip to Main Content

Biogen is moving to scale back its real estate footprint in Kendall Square and in Weston, as the Cambridge-based biotech company aims to cut $1 billion in costs in the wake of a disastrous rollout of its Alzheimer’s drug Aduhelm.

Biogen is looking to sublease more than 183,000 square feet at 300 Binney St. in Cambridge — across the street from its headquarters — and is also subleasing two floors, or 80,000 square feet, at one of its two properties at 133 Boston Pond Road in Weston.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment